Vaccines, blood, antisera, toxins and cultures in   United States

Overview In January 2024 United States' Vaccines, blood, antisera, toxins and cultures exports accounted up to $3.82B and imports accounted up to $7.96B, resulting in a negative trade balance of $4.14B. Between January 2023 and January 2024 the exports of United States'   Vaccines, blood, antisera, toxins and cultures have decreased by $-341M (-8.2%) from $4.16B to $3.82B, while imports increased by $1.39B (21.1%) from $6.57B to $7.96B.

Destinations In January 2024, Vaccines, blood, antisera, toxins and cultures were exported mostly to China ($634M), Germany ($441M), Netherlands ($316M), Ireland ($256M), and Japan ($208M), and were imported mostly from Ireland ($2.37B), Germany ($1.06B), Singapore ($774M), Switzerland ($749M), and Netherlands ($529M).

Growth In January 2024, the decrease in Vaccines, blood, antisera, toxins and cultures's year-by-year exports was explained primarily by a decrease in exports to Canada ($-330M or -74.5%), Spain ($-132M or -61%), and Nigeria ($-125M or -99.8%). In January 2024, the increase in Vaccines, blood, antisera, toxins and cultures's year-by-year imports was explained primarily by an increase in imports from Netherlands ($663M or 375%), Ireland ($572M or 41.4%), and Germany ($379M or 60.8%).